Eli Lilly and Company (LLY) stock analysis

Healthcare · Drug Manufacturers - General

From the 10-K filed 2026-02-12

How it makes money

Mounjaro and Zepbound incretins generate 56 percent of revenue, distributed largely through three U.S. wholesalers that each account for a significant share of sales.

Incretin medicines Mounjaro and Zepbound now provide over half of the company's revenue, signaling a structural shift toward the cardiometabolic health segment. Most of these products flow through three massive U.S. wholesalers—McKesson, Cencora, and Cardinal Health—which act as the primary nodes between the company and healthcare providers.

Profit is heavily influenced by the mix between volume growth and realized price. While demand for weight-loss and diabetes treatments is surging, net prices are often reduced by rebates and discounts negotiated with pharmacy benefit managers and insurers to secure favorable formulary placement.

What protects it: the moat

It relies on compound patents and regulatory data protection to maintain market exclusivity for its branded pharmaceuticals against generic and biosimilar competition.

The company defends its earnings through compound patents and regulatory data exclusivity periods. For biologics, this protection is bolstered by a 12-year data package protection period in the U.S. during which biosimilar manufacturers cannot rely on the company's clinical data for approval.

These legal barriers are essential because generic and biosimilar competitors invest significantly fewer resources in research and development, allowing them to price versions of the same molecules much lower once market exclusivity expires.

What growth costs

It is funding significant manufacturing expansion initiatives to meet demand for its cardiometabolic products while increasing research and development and marketing spend.

To sustain growth, the company is making multi-billion dollar investments in manufacturing infrastructure to scale production of its incretin portfolio. It also faces high research and development costs to progress molecules like orforglipron through phase 3 trials.

Marketing and selling expenses are a significant requirement to educate healthcare providers and manage direct-to-patient platforms like LillyDirect to navigate complex private sector insurance dynamics.

What could damage it

Government-set prices for Jardiance in 2026 and Trulicity in 2028 under the Inflation Reduction Act could materially reduce its realized pricing.

The primary risk of permanent impairment comes from the U.S. government's authority to effectively set prices for top-selling drugs. Unlike traditional negotiations, this allows the Department of Health and Human Services to mandate prices for products like Jardiance and Trulicity that have been on the market for several years.

Additionally, the proliferation of mass-compounded and counterfeit versions of incretin medicines could erode the company's pricing power and damage its brand reputation if patient safety issues arise from non-genuine products.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

More on LLY

Other companies in Drug Manufacturers - General